Cargando…

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review

Ovarian cancer is the most common cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease; although chemotherapeutic advances have improved progression-free survival, conventional treatments offer limited results in terms of long-term responses an...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Claudia, Palaia, Innocenza, Giorgini, Margherita, De Medici, Caterina, Iadarola, Roberta, Vertechy, Laura, Domenici, Lavinia, Di Donato, Violante, Tomao, Federica, Muzii, Ludovico, Benedetti Panici, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096491/
https://www.ncbi.nlm.nih.gov/pubmed/25031539
http://dx.doi.org/10.2147/OTT.S40947
_version_ 1782326145369243648
author Marchetti, Claudia
Palaia, Innocenza
Giorgini, Margherita
De Medici, Caterina
Iadarola, Roberta
Vertechy, Laura
Domenici, Lavinia
Di Donato, Violante
Tomao, Federica
Muzii, Ludovico
Benedetti Panici, Pierluigi
author_facet Marchetti, Claudia
Palaia, Innocenza
Giorgini, Margherita
De Medici, Caterina
Iadarola, Roberta
Vertechy, Laura
Domenici, Lavinia
Di Donato, Violante
Tomao, Federica
Muzii, Ludovico
Benedetti Panici, Pierluigi
author_sort Marchetti, Claudia
collection PubMed
description Ovarian cancer is the most common cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease; although chemotherapeutic advances have improved progression-free survival, conventional treatments offer limited results in terms of long-term responses and survival. Research has recently focused on targeted therapies, which represent a new, promising therapeutic approach, aimed to maximize tumor kill and minimize toxicity. Besides antiangiogenetic agents and poly (ADP-ribose) polymerase inhibitors, the folate, with its membrane-bound receptor, is currently one of the most investigated alternatives. In particular, folate receptor (FR) has been shown to be frequently overexpressed on the surface of almost all epithelial ovarian cancers, making this receptor an excellent tumor-associated antigen. There are two basic strategies to targeting FRs with therapeutic intent: the first is based on anti-FR antibody (ie, farletuzumab) and the second is based on folate–chemotherapy conjugates (ie, vintafolide/etarfolatide). Both strategies have been investigated in Phase III clinical trials. The aim of this review is to analyze the research regarding the activity of these promising anti-FR agents in patients affected by ovarian cancer, including anti-FR antibodies and folate–chemotherapy conjugates.
format Online
Article
Text
id pubmed-4096491
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40964912014-07-16 Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review Marchetti, Claudia Palaia, Innocenza Giorgini, Margherita De Medici, Caterina Iadarola, Roberta Vertechy, Laura Domenici, Lavinia Di Donato, Violante Tomao, Federica Muzii, Ludovico Benedetti Panici, Pierluigi Onco Targets Ther Review Ovarian cancer is the most common cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease; although chemotherapeutic advances have improved progression-free survival, conventional treatments offer limited results in terms of long-term responses and survival. Research has recently focused on targeted therapies, which represent a new, promising therapeutic approach, aimed to maximize tumor kill and minimize toxicity. Besides antiangiogenetic agents and poly (ADP-ribose) polymerase inhibitors, the folate, with its membrane-bound receptor, is currently one of the most investigated alternatives. In particular, folate receptor (FR) has been shown to be frequently overexpressed on the surface of almost all epithelial ovarian cancers, making this receptor an excellent tumor-associated antigen. There are two basic strategies to targeting FRs with therapeutic intent: the first is based on anti-FR antibody (ie, farletuzumab) and the second is based on folate–chemotherapy conjugates (ie, vintafolide/etarfolatide). Both strategies have been investigated in Phase III clinical trials. The aim of this review is to analyze the research regarding the activity of these promising anti-FR agents in patients affected by ovarian cancer, including anti-FR antibodies and folate–chemotherapy conjugates. Dove Medical Press 2014-07-10 /pmc/articles/PMC4096491/ /pubmed/25031539 http://dx.doi.org/10.2147/OTT.S40947 Text en © 2014 Marchetti et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Marchetti, Claudia
Palaia, Innocenza
Giorgini, Margherita
De Medici, Caterina
Iadarola, Roberta
Vertechy, Laura
Domenici, Lavinia
Di Donato, Violante
Tomao, Federica
Muzii, Ludovico
Benedetti Panici, Pierluigi
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
title Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
title_full Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
title_fullStr Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
title_full_unstemmed Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
title_short Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
title_sort targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096491/
https://www.ncbi.nlm.nih.gov/pubmed/25031539
http://dx.doi.org/10.2147/OTT.S40947
work_keys_str_mv AT marchetticlaudia targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT palaiainnocenza targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT giorginimargherita targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT demedicicaterina targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT iadarolaroberta targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT vertechylaura targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT domenicilavinia targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT didonatoviolante targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT tomaofederica targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT muziiludovico targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview
AT benedettipanicipierluigi targeteddrugdeliveryviafolatereceptorsinrecurrentovariancancerareview